August 15, 2018
Pharma companies racing to develop new drugs to combat fatty liver diseases, such as steatosis, NASH, and fibrosis, need better preclinical testing tools for compound screening and mechanistic studies. Here’s […]
July 18, 2018
Correlating human pancreas donor characteristics with 3D InSight™ Islet Microtissue functionality confirms reaggregated islets are a robust, physiologically relevant model for diabetes research. With diabetes approaching epidemic proportions globally, there […]
June 29, 2018
InSphero and Agilent discuss the need for metabolically competent models with stable metabolic activity for mitochondrial toxicity testing in a new textbook chapter. Mitochondrial Dysfunction Caused by Drugs and Environmental […]
June 18, 2018
In honor of the inaugural International NASH Day, an initiative to raise awareness of nonalcoholic steatohepatitis (NASH), I thought it would be appropriate to reflect on the current status of […]
May 29, 2018
Landmark study comparing 2D and 3D DILI models shows 3D InSight™ Human Liver Microtissues are a highly predictive liver toxicology model that outperforms 2D primary human hepatocytes in culture. In […]
May 28, 2018
InSphero Akura™ Flow body-on-a-chip technology may help make animal testing in pharma and cosmetic companies obsolete How can we better predict how new drugs act in the human body? This […]